Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezepelumab for Bronchiolitis Obliterans Syndrome in HSCT Recipients
NCT07771855Phase 2Recruiting
- Sponsor
- Hôpital Foch
- Start
- Jun 2026
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
A Phase 2 trial of tezepelumab in Bronchiolitis Obliterans Syndrome (BOS), sponsored by Hôpital Foch. Started Jun 2026; status: recruiting.
02
Drugs
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on NCT07771855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07771855.